NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell DeathData Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE) -- ...

NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell Death Data Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738 BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE) ...

If approved in RCC, fruquintinib will be available for three indications, including endometrial and colorectal cancer.

Celltrion announced on the 31st that it has signed a joint research and development agreement for a new immuno-oncology drug with MustBio, a domestic ...

Partial remissions and complete metabolic responses in PD-1/PD-L1-resistant cancers First-in-class multi-checkpoint inhibitor with robust ...

The understanding of immune biology and the development of newer generations of immunotherapies have opened a new stage to ...

NUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated Patients Latest Data Cut-Off Shows ...

NuCana (NCNA) presented data at the European Society for Medical Oncology Congress 2025, ESMO, on a new model system investigating the synergistic ...

Camrelizumab and famitinib are projected to achieve global annual sales of $463 million and $108 million by 2031.

A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body’s ...

A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's ...